BMS Receives FDA Approval for Sotyktu in Psoriatic Arthritis Treatment on March 11, 2026 Approved Arthritis, Psoriatic deucravacitinib Myers Squibb Oral Medication Sotyktu TYK2 inhibitor United States Food and Drug Administration +
J&J's Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials on September 17, 2025 Dental Plaque deucravacitinib IL-23 receptor antagonist JNJ-2113 Johnson & Johnson Myers oral peptide Phase 3 clinical trial Psoriasis skin clearance Sotyktu +
Sotyktu Shows Promise in Phase 3 Psoriatic Arthritis Trial on March 10, 2025 Arthritis deucravacitinib Inhibitor Myers POETYK PsA-2 trial Psoriatic Sotyktu squibb TYK2 gene +